New combo drug trial for Tough-to-Treat ovarian cancer halted
NCT ID NCT05200364
Summary
This early-stage trial tested the safety and best dose of a new drug, STRO-002, when given with an existing cancer drug, bevacizumab. It was for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that had come back or stopped responding to standard treatments. The main goal was to see if the two-drug combination was safe and tolerable for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19017, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of South Florida,
Tampa, Florida, 33612, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.